Semaglutide vs Tirzepatide: Comparación de agonistas GLP-1

Introduction: The GLP-1 Revolution

Semaglutide and tirzepatide represent the current frontier of incretin-based therapies for type 2 diabetes and obesity. Both have achieved blockbuster status and fundamentally altered the treatment landscape for metabolic disease. However, they differ in their receptor pharmacology, clinical trial results, dosing schedules, and cost profiles. This article provides a research-oriented comparison to help readers understand the scientific distinctions between these two compounds.

For individual deep dives, see our articles on semaglutide and tirzepatide.

Comparison Table

Property	Semaglutide	Tirzepatide
Drug Class	GLP-1 receptor agonist (single)	GLP-1/GIP dual receptor agonist (twincretin)
Manufacturer	Novo Nordisk	Eli Lilly
Brand Names	Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral)	Mounjaro (diabetes), Zepbound (obesity)
Mechanism	Activates GLP-1 receptors to increase insulin, reduce glucagon, slow gastric emptying, reduce appetite	Activates both GLP-1 and GIP receptors; GIP adds enhanced insulin secretion, potential adipose tissue effects, and may improve GI tolerability
Administration	Weekly subcutaneous injection; oral tablet available (Rybelsus)	Weekly subcutaneous injection
Max Dose	2.4 mg/week (Wegovy)	15 mg/week (Zepbound/Mounjaro)
Key Weight Loss Trial	STEP 1: 16.9% mean weight loss at 68 weeks	SURMOUNT-1: 22.5% mean weight loss at 72 weeks (15 mg dose)
HbA1c Reduction	Up to 1.8% (SUSTAIN trials)	Up to 2.58% (SURPASS-2)
FDA Approval (Diabetes)	2017 (Ozempic)	2022 (Mounjaro)
FDA Approval (Obesity)	2021 (Wegovy)	2023 (Zepbound)
Oral Formulation	Yes (Rybelsus, 7 mg or 14 mg daily)	In development (oral tirzepatide Phase 3)
Cardiovascular Data	SELECT trial: 20% reduction in MACE	SURPASS-CVOT ongoing; interim data promising
Estimated Monthly Cost (US)	$900-$1,350 (without insurance)	$1,000-$1,200 (without insurance)

Mechanism Comparison: Single vs Dual Agonism

Semaglutide: Optimized GLP-1 Agonism

Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native human GLP-1. Through strategic modifications, including an amino acid substitution at position 8 (Aib replacing Ala) and a C-18 fatty diacid chain, semaglutide achieves strong albumin binding and resistance to DPP-4 degradation, resulting in a half-life of approximately 7 days. This enables once-weekly dosing.

Its mechanism centers on a single receptor: GLP-1R. Activation of this receptor in the pancreas enhances glucose-dependent insulin secretion and suppresses glucagon. In the brain, GLP-1R activation in the hypothalamus and brainstem reduces appetite and food intake. Semaglutide also slows gastric emptying, contributing to post-meal satiety.

Tirzepatide: The Twincretin Approach

Tirzepatide was designed as a dual GLP-1/GIP receptor agonist, sometimes called a "twincretin." Its 39-amino-acid sequence is based on native GIP but engineered to also activate GLP-1 receptors. A C-20 fatty diacid moiety enables albumin binding and an approximately 5-day half-life suitable for weekly injection.

The addition of GIP receptor agonism introduces several differentiating effects. GIP receptors are expressed on pancreatic beta cells (enhancing insulin secretion), adipose tissue (potentially improving lipid storage and adipose function), and bone (where GIP has anabolic effects). The dual mechanism may explain tirzepatide's greater glucose-lowering and weight-loss efficacy observed in clinical trials, though the exact contribution of each receptor pathway remains an active area of investigation.

One hypothesis for tirzepatide's improved GI tolerability at high efficacy doses is that GIP receptor activation may partially counterbalance the nausea-inducing effects of GLP-1 receptor activation, though this has not been definitively established.

Clinical Trial Comparison

Weight Loss: STEP vs SURMOUNT

The STEP (Semaglutide Treatment Effect in People with obesity) and SURMOUNT (tirzepatide) trial programs represent the largest clinical trial datasets for these compounds in obesity.

STEP 1 enrolled 1,961 adults with obesity (BMI of 30 or above, or 27 with at least one weight-related comorbidity) and demonstrated 16.9% mean body weight loss with semaglutide 2.4 mg over 68 weeks versus 2.4% with placebo. Notably, 86.4% of participants achieved at least 5% weight loss, and 69.1% achieved at least 10%.

SURMOUNT-1 enrolled 2,539 adults with similar criteria and showed dose-dependent weight loss: 15.0% with tirzepatide 5 mg, 19.5% with 10 mg, and 22.5% with 15 mg over 72 weeks, compared to 3.1% with placebo. At the highest dose, 62.9% of participants achieved at least 20% weight loss.

While these results appear to favor tirzepatide, direct comparison is complicated by differences in trial design, patient populations, treatment durations, and dosing titration schedules. The SURMOUNT-4 trial provided additional evidence of tirzepatide's sustained effects, showing significant weight regain after discontinuation, a pattern also observed with semaglutide in STEP 1 extension data.

Diabetes: SUSTAIN vs SURPASS

In type 2 diabetes, both compounds demonstrated substantial HbA1c reductions. The SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg (not the maximum 2 mg dose available at the time), showed tirzepatide achieving greater HbA1c reductions and weight loss at all three doses tested. However, researchers have noted that a comparison against the full 2 mg or 2.4 mg semaglutide dose would be needed for a complete assessment.

Cardiovascular Outcomes

Semaglutide currently has a significant advantage in cardiovascular evidence. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and obesity without diabetes. This led to an expanded indication for cardiovascular risk reduction.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with preliminary data expected. Until this trial reports, semaglutide maintains a more robust cardiovascular evidence base.

Side Effect Comparison

Both semaglutide and tirzepatide share the same general side effect profile characteristic of GLP-1 receptor agonists, predominantly gastrointestinal in nature:

• Nausea: Reported in approximately 44% of semaglutide (STEP 1) and 24-33% of tirzepatide (SURMOUNT-1, dose-dependent) participants. Nausea typically peaks during dose escalation and diminishes over time.
• Vomiting: Approximately 24% with semaglutide and 9-13% with tirzepatide at highest doses.
• Diarrhea: Approximately 30% with semaglutide and 18-23% with tirzepatide.
• Constipation: Approximately 24% with semaglutide and 11-17% with tirzepatide.

Both compounds carry warnings for pancreatitis risk, thyroid C-cell tumor risk (observed in rodent studies with GLP-1 agonists, clinical relevance uncertain), and gallbladder-related events. Discontinuation rates due to adverse events were similar across both trial programs, generally ranging from 4-7%.

Cost and Access Considerations

As of early 2026, both medications carry substantial list prices in the United States. Insurance coverage varies significantly by plan, indication (diabetes vs. obesity), and formulary status. Some relevant factors:

• Semaglutide has been on the market longer, resulting in broader insurance coverage and more established prior authorization pathways.
• Tirzepatide has faced periodic supply constraints since launch.
• Oral semaglutide (Rybelsus) offers an alternative for patients who prefer not to inject, though the oral formulation's bioavailability is lower and dosing is currently approved only for diabetes.
• Competition between the two drugs has prompted manufacturer discount programs, though out-of-pocket costs remain significant for many patients.

Verdict: Which Compound for Which Context?

Winner for Maximum Weight Loss Efficacy: Tirzepatide

Based on available clinical trial data, tirzepatide at its highest approved dose has demonstrated greater mean weight loss than semaglutide at its highest approved dose. The dual receptor mechanism appears to confer an efficacy advantage.

Winner for Cardiovascular Evidence: Semaglutide

With the completed SELECT trial demonstrating a clear MACE reduction, semaglutide has the stronger cardiovascular evidence base. This may change when tirzepatide's CVOT trial reports.

Winner for Oral Administration: Semaglutide

Rybelsus remains the only approved oral GLP-1 agonist. Oral tirzepatide is in development but not yet available.

Winner for GI Tolerability: Tirzepatide (Tentative)

Cross-trial comparisons suggest lower rates of nausea and vomiting with tirzepatide, possibly related to GIP receptor activation. However, this requires confirmation from dedicated head-to-head tolerability studies.

For broader context on this drug class, see our Complete Guide to GLP-1 Receptor Agonists.